Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.